Research
Medicilon completed full sets of non-clinical research projects for new drugs such as ophthalmic solutions or intravitreal injections
Medicilon has been conducting comprehensive non-clinical research for ophthalmic drugs since 2013, with extensive experience from active pharmaceutical ingredients and formulations to pharmacodynamics, pharmacokinetics, and safety assessments, and has contributed to the approval of mult...
Navigating Consumer Minds: How to increase the likelihood of purchase and instil behaviour change.
Cathrine Jansson-Boyd is an academic teaching and conducting research in Consumer Psychology. In her inaugural Professorial lecture, Cathrine will present research topics and findings drawn from her time as an academic. ...
Deloitte Cambridge and Castle Manor Academy in Haverhill announce new partnership
Deloitte Cambridge and Castle Manor Academy in Haverhill are delighted to announce a new partnership, part of the firm’s 5 Million Futures programme. ...
Cambridge AI Club for Biomedicine - December 2024
The AI Club brings together the Biomedical AI and Machine Learning community in Cambridge, to discuss common themes and explore different topics and methodologies. Talks will be followed by pizza and networking. ...
High opacity micro 3D printing - Tough Carbon Black
Revolutionizing Micro 3D Printing with Tough Carbon Black
Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent y...
Cambridge NeuroWorks Launch Event - Powered by ARIA
Join us for the launch of Cambridge NeuroWorks, an ambitious multi-million-pound, three-year partnership with the Advanced Research and Invention Agency (ARIA) to revolutionise neurotechnology. ...
Combating antibiotic resistance through ligand- and structure-based virtual screening
Date: Tuesday 3rd December 2024 Time: 2pm GMT / 3pm CET / 9am ET / 7am PT Physics-based virtual screening has substantially enhanced the drug discovery process by enabling precise predictions of ligand-receptor interactions, thereby reducing the computational cost and time associated w...
Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects Glasgow, UK, 20 November...
COPD management: a critical look at gaps in pharmaceutical innovation
Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care. ...